GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » EV-to-FCF

Novaccess Global (Novaccess Global) EV-to-FCF : -7.75 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novaccess Global's Enterprise Value is $2.86 Mil. Novaccess Global's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.37 Mil. Therefore, Novaccess Global's EV-to-FCF for today is -7.75.

The historical rank and industry rank for Novaccess Global's EV-to-FCF or its related term are showing as below:

XSNX' s EV-to-FCF Range Over the Past 10 Years
Min: -276.62   Med: -8.01   Max: 172.97
Current: -7.53

During the past 13 years, the highest EV-to-FCF of Novaccess Global was 172.97. The lowest was -276.62. And the median was -8.01.

XSNX's EV-to-FCF is ranked worse than
100% of 367 companies
in the Biotechnology industry
Industry Median: 9.77 vs XSNX: -7.53

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Novaccess Global's stock price is $0.014. Novaccess Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.130. Therefore, Novaccess Global's PE Ratio for today is At Loss.


Novaccess Global EV-to-FCF Historical Data

The historical data trend for Novaccess Global's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global EV-to-FCF Chart

Novaccess Global Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -112.66 -14.68 -9.99 -3.84 -6.97

Novaccess Global Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.66 -6.32 -6.97 -5.28 -6.67

Competitive Comparison of Novaccess Global's EV-to-FCF

For the Biotechnology subindustry, Novaccess Global's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novaccess Global's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novaccess Global's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Novaccess Global's EV-to-FCF falls into.



Novaccess Global EV-to-FCF Calculation

Novaccess Global's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.859/-0.369
=-7.75

Novaccess Global's current Enterprise Value is $2.86 Mil.
Novaccess Global's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novaccess Global  (OTCPK:XSNX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Novaccess Global's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.014/-0.130
=At Loss

Novaccess Global's share price for today is $0.014.
Novaccess Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Novaccess Global EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Novaccess Global's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novaccess Global (Novaccess Global) Business Description

Traded in Other Exchanges
N/A
Address
8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404